Skip to content
Biodatica
Start free

Ascentage Pharma Group Inc.

Jacksonville, Florida

OncologyPhase II
Compare Sign in to watch

What changed

Study registered, no phase assigned: Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

4mo agoTrial registeredMar 16, 2026Source filing (opens the source filing in a new tab)

Momentum

74no change

Momentum 74 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,034 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Mar 10, 2026

    Indolent Lymphoma, WM, MZL, CLL / SLL · NOT_YET_RECRUITING · sponsor: Henan Cancer Hospital · Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

    ClinicalTrials.gov · NCT07459608 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Mar 10, 2026

    DLBCL - Diffuse Large B Cell Lymphoma · NOT_YET_RECRUITING · sponsor: Henan Cancer Hospital · Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

    ClinicalTrials.gov · NCT07472621 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Mar 1, 2026

    Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL), Relapsed/Refractory Waldenström Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Relapsed/Refractory Follicular Lymphoma (FL) · NOT_YET_RECRUITING · sponsor: Ascentage Pharma Group Inc. · A Study of APG-3288 in Relapsed/Refractory Blood Cancers

    ClinicalTrials.gov · NCT07424833 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources